Zobrazeno 1 - 10
of 62
pro vyhledávání: ''
Autor:
Shigeyuki Miyamura, Tomoko Ushijima, Daisuke Kadowaki, Kentaro Oniki, Shinsuke Hamada, Fumihiro Nishimura, Junji Saruwatari
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 46:1622-1628
What is known and objective Cisplatin-based chemotherapy is a first-line treatment for advanced or metastatic urinary tract urothelial carcinoma (UC). Accurate assessment of renal function is indispensable for determining cisplatin dosing to enhance
Autor:
El-Sayed M. El-Sayed, Gouda K. Helal, Khalid S. Hassanien, Zakarya M. Zakarya, Raed S. Ismail
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 46:942-949
WHAT IS KNOWN AND OBJECTIVE Sofosbuvir has been approved as the first nonstructural protein 5B polymerase inhibitor with pan-genotypic activity against the hepatitis C (HCV) virus. Daclatasvir is a first-in-class hepatitis C virus nonstructural prote
Autor:
Kocayiğit, Havva, Özmen Süner, Kezban, Tomak, Yakup, Demir, Gürkan, Yaylacı, Selçuk, Dheir, Hamad, Güçlü, Ertuğrul, Erdem, Ali Fuat
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics
What is known and objectives In November 2019, several patients were diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China. So far, there are no specific treatments with proven high efficacy in patients with SARS
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 46:328-332
WHAT IS KNOWN AND OBJECTIVE Cilostazol is a specific and strong inhibitor of phosphodiesterase (PDE) type III which can suppress the platelet aggregation by increasing cyclic adenosine monophosphate (cAMP) levels. The clinical benefit of cilostazol i
Autor:
Jae Hyoung Cho, Seung-Hwan Lee, Ju Han Kim, Suehyun Lee, Hyeon Woo Yim, Hyunyong Lee, Jeongmin Lee, Hyunah Kim, Kun Ho Yoon, Hun-Sung Kim
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 46:134-142
WHAT IS KNOWN AND OBJECTIVES This study investigated the additional low-density lipoprotein cholesterol (LDL-C) reductions and target (LDL-C
Autor:
Zhifeng Zhu, Jie Fan, Jiyang Xue, Hongjuan Xie, Pu Zhao, Xuefeng Hu, Aijie Guo, Liping Huang, Xuemei Di
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 45:1414-1421
What is known and objectives Caffeine citrate is a commonly used methylxanthine for pharmacologic treatment of apnea of prematurity. The aim of this study was to develop and verify a population pharmacokinetic (PPK) model, which can provide a referen
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 45:1390-1397
WHAT IS KNOWN AND OBJECTIVE Cystatin C (Cys-C) is a useful diagnostic marker for early renal dysfunction, but has the disadvantage of giving false-positive results when corticosteroids are administered. In this study, we aimed to evaluate the dose-de
Autor:
Kelly L Niggebrugge-Mentink, Peter G J Ter Horst, Charlotte van Kesteren, Marieke M. Beex-Oosterhuis, Hetty G Dieleman, Matthijs E C van de Poll
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 45:1153-1158
WHAT IS KNOWN AND OBJECTIVE Nephrotoxicity is a frequently occurring side effect of cisplatin, which may be reduced by applying ample hydration. The aim of this study was to determine whether there is a difference in decline in renal function due to
Autor:
Takuya Yamashina, Yosei Kawamata, Hiroko Tsukada, Shinya Takashima, Yoichi Hiraki, Moeko Tsuruyama, Masahisa Nagano, Airi Fujimoto, Minako Tsuruta
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 45:1143-1148
What is known and objective We investigated the elimination efficiency and pharmacokinetics (PK) parameters of vancomycin (VCM) in patients undergoing continuous haemodiafiltration (CHDF) using a polyethyleneimine-coated polyacrylonitrile membrane (A
Autor:
Sara Hassan Agwa, Abdel-Hameed I. Mohammed Ebid, Osama Ashraf Ahmed, Amira Elsawy, Sara Mohamed Abdel-Motaleb, Radwa Samir Hagag
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 45:539-546
What is known and objective Direct-acting antivirals (DAAs) have become the most widely used treatment of chronic hepatitis C infection. Comparative studies on DAAs regimens approved by the Egyptian Ministry of Health for easy-to-treat genotype 4 (G4